PPARGC1A and metabolic syndrome: Furthermore, a PGC-1α activator which selectively increases PGC-1α expression in myotubes and skeletal muscle increases fatty acid oxidation and ameliorates pyruvate tolerance, glucose tolerance, insulin sensitivity, hyperglycemia, and dyslipidemia [9].